

The Adverse Effects of Mild-to-Moderate Iodine Deficiency during Pregnancy and Childhood: A Review

Michael B. Zimmermann

Iodine is required for the production of thyroid hormones, which are essential for normal brain development, and the fetus, newborn, and young child are particularly vulnerable to iodine deficiency. The iodine requirement increases during pregnancy and recommended intakes are in the range of 220–250 $\mu\text{g}/\text{day}$. Monitoring iodine status during pregnancy is a challenge. New recommendations from World Health Organization suggest that a median urinary iodine concentration $>250 \mu\text{g}/\text{L}$ and $<500 \mu\text{g}/\text{L}$ indicates adequate iodine intake in pregnancy. Based on this range, it appears that many pregnant women in Western Europe have inadequate intakes. A recent Swiss study has suggested that thyroid-stimulating hormone concentration in the newborn is a sensitive indicator of mild iodine deficiency in late pregnancy. The potential adverse effects of mild iodine deficiency during pregnancy are uncertain. Controlled trials of iodine supplementation in mildly iodine-deficient pregnant women suggest beneficial effects on maternal and newborn serum thyroglobulin and thyroid volume, but no effects on maternal and newborn total or free thyroid hormone concentrations. There are no long-term data on the effect of iodine supplementation on birth outcomes or infant development. New data from well-controlled studies indicate that iodine repletion in moderately iodine-deficient school-age children has clear benefits: it improves cognitive and motor function; it also increases concentrations of insulin-like growth factor 1 and insulin-like growth factor-binding protein 3, and improves somatic growth.

Introduction

IODINE IS REQUIRED FOR THE PRODUCTION OF thyroid hormones, which are essential for normal brain development, and the fetus and newborn are particularly vulnerable to iodine deficiency (1). In regions of severe endemic goiter, the adverse effects of *in utero* iodine deficiency on neuromotor development are well established: randomized controlled trials of iodine supplements given to iodine-deficient mothers before pregnancy or during early pregnancy improved motor and cognitive performance of their offspring (2–4). However, the potential adverse effects of mild-to-moderate iodine deficiency during pregnancy are less clear.

Fetal and newborn hypothyroxinemia are the likely cause of brain damage due to iodine deficiency. Maternal thyroxine (T₄) crosses the placenta to support neural development before onset of fetal thyroid function at 10–12 weeks (5). Maternal T₄ represents up to 20–40% of T₄ measured in cord blood at birth (6). Maternal subclinical hypothyroidism [an increased thyroid-stimulating hormone (TSH) in the second trimester] and maternal hypothyroxinemia [a free T₄ (FT₄) concentration <10 percentile at 12-week gestation] are associ-

ated with impaired mental/psychomotor development of the offspring (7,8). However, in these studies, the maternal thyroid abnormalities were not apparently due to iodine deficiency.

Iodine Requirements in Pregnancy

The iodine requirement during pregnancy is increased due to an increase in maternal T₄ production to maintain maternal euthyroidism and transfer of thyroid hormone to the fetus, and iodine transfer to the fetus, particularly in later gestation (9). There may also be an increase in renal iodine clearance during pregnancy, although this is unclear (10,11). Several methods have been used to estimate iodine requirements in pregnancy. The thyroidal iodine accumulation by the infant at delivery has been used to estimate the daily fetal iodine uptake. Added to the estimated average requirement (EAR) of 95 $\mu\text{g}/\text{day}$ for nonpregnant women, a daily fetal thyroid iodine uptake of $\approx 75 \mu\text{g}/\text{day}$ would suggest an EAR of 170 $\mu\text{g}/\text{day}$ for pregnancy (12). Dworkin *et al.* (13) reported that pregnant women were in iodine balance when consuming $\approx 160 \mu\text{g}/\text{day}$. In the United States, the EAR for iodine has been set at 160 $\mu\text{g}/\text{day}$ for pregnant women

TABLE 1. THE WHO DAILY RECOMMENDED NUTRIENT INTAKE FOR IODINE PROPOSED FOR PREGNANT WOMEN AND THE EXCESSIVE DAILY INTAKE (REF. 15), AND THE U.S. INSTITUTE OF MEDICINE (IOM) ESTIMATED AVERAGE REQUIREMENT AND RECOMMENDED DIETARY ALLOWANCE (REF. 12) FOR PREGNANT WOMEN

Organization	$\mu\text{g}/\text{day}$
WHO (2006)	
Recommended nutrient intake	250
Excessive intake	500
U.S. IOM (2001)	
Estimated average requirement (EAR)	160
Recommended dietary allowance (RDA)	220

≥ 14 years, and the recommended dietary allowance, set at 140% of the EAR rounded to the nearest 10 μg , is 220 $\mu\text{g}/\text{day}$ (Table 1) (12). In 2001, World Health Organization (WHO)/International Council for Control of Iodine Deficiency Disorders (ICCIDD)/United Nations International Children's Emergency Fund (UNICEF) recommended a daily iodine intake of 200 μg for pregnant women (14). However, a recent WHO technical consultation has increased the recommended iodine intake for pregnant women to 250 $\mu\text{g}/\text{day}$ (Table 1) (15).

Defining "Mild-to-Moderate" Iodine Deficiency in Pregnancy

The median urinary iodine concentration (UI) is recommended by WHO/ICCIDD/UNICEF (14) for assessing iodine nutrition in populations. Daily iodine intake can be extrapolated from UI assuming median 24-hour urine volumes for girls aged 7–15 years of 0.9 mL/(hr kg) (16), and for adult women of ≈ 1.5 L (17). Assuming a mean iodine bioavailability of 92% and a modest increase in renal iodine clearance during pregnancy (10,11,18), recommended daily iodine intakes for pregnancy of 200–250 μg (12,14,15) correspond to a median UI of ≥ 150 $\mu\text{g}/\text{L}$ in adult pregnant women (15). New recommendations from WHO state a median UI of 150–250 $\mu\text{g}/\text{L}$, which indicates adequate iodine intake in pregnancy (Table 2) (15). Thus, mild-to-moderate deficiency in pregnancy can be defined as a median UI of 50–150 $\mu\text{g}/\text{L}$. In National Health and Nutrition Examination Survey III (NHANES III), among pregnant women in the United States, 7% had a spot UI < 50 $\mu\text{g}/\text{L}$ (19). However, this should be interpreted with caution, as spot UIs tend to overestimate low and high intakes in a population (20). Moreover, among 15- to 44-year-old women in NHANES III, including pregnant women, there were no

TABLE 2. THE MEDIAN OR RANGE IN URINARY IODINE CONCENTRATIONS USED TO CATEGORIZE THE IODINE INTAKE OF PREGNANT WOMEN (DATA FROM REF. 15)

Population group	Median urinary iodine concentration ($\mu\text{g}/\text{L}$)	Category of iodine intake
Pregnant women	< 150	Insufficient
	150–249	Adequate
	250–499	More than adequate
	≥ 500	Excessive

differences in TSH or T4 comparing those with a UI < 50 $\mu\text{g}/\text{L}$ and those with higher values (21).

Newborn TSH Concentrations Are a Sensitive Indicator of Iodine Nutrition during Pregnancy

Along with determination of the median UI in pregnant women, TSH screening in newborns may be useful in assessing iodine status in late pregnancy (22–27). In iodine-sufficient populations in Australia and Canada, the prevalence of elevated TSH concentrations (> 5 mU/L, with the use of a sensitive monoclonal antibody assay) in blood filter paper specimens collected ≥ 3 days after birth was between 3% and 5% (23). However, multiple factors other than maternal iodine status can influence measurements of TSH concentrations in newborns, including timing of specimen collection, maternal or newborn exposure to iodine-containing antiseptics, and the TSH assay and collection paper used (26). Because of these uncertainties, the cutoffs for defining severity of iodine deficiency on the basis of newborn TSH concentrations originally proposed by the WHO (28) were not included in the most recent recommendations (14,15).

In Switzerland, because of declining iodine intakes in children and pregnant women, the iodine concentration in table salt was increased from 15 to 20 mg/kg in 1999. A recent prospective national study has evaluated UI in pregnant women, 5 years after the increase in the salt iodine concentration. In addition, the frequency of elevated TSH concentrations found in the newborn screening program was evaluated before and after the increase (29). In this program, whole-blood samples obtained on day 3 or 4 (72–96 hours) after birth are spotted and dried on filter paper and sent to a central laboratory. In 1999, before the salt iodine increase, the median UI among pregnant women was 138 $\mu\text{g}/\text{L}$, suggesting mild iodine deficiency. In 2004, median UI in pregnancy had increased significantly to 249 $\mu\text{g}/\text{L}$, indicating sufficiency. In 1992–1998, when iodine status was marginal in Switzerland, the prevalence of newborn TSH concentrations > 5 mU/L was 2.9% ($n = 259,035$). After the increase in salt iodine content, the prevalence decreased to 1.7% in 1999–2004 ($n = 218,665$) ($p < 0.0001$) (Table 3). Thus, an increase in iodine concentration in iodized table salt markedly improved iodine status of pregnant women in Switzerland, and this improvement was reflected in the reduced frequency of newborn TSH values > 5 mU/L. These data suggest that newborn TSH, obtained with the use of a sensitive assay on samples collected 3–4 days after birth, is a sensitive indicator of iodine nutrition during pregnancy (29). These data also support the original WHO recommendation that a $< 3\%$ frequency of TSH values > 5 mU/L indicates iodine sufficiency in a population (28).

Mild-to-Moderate Iodine Deficiency in Pregnancy: Intervention Studies

In Europe, six randomized controlled trials of iodine supplementation in pregnancy have been published, involving 450 women with mild-to-moderate iodine deficiency (30–35). Romano *et al.* (30) gave 120–180 μg iodine as iodized salt or control daily beginning in the first trimester to healthy pregnant women ($n = 35$; median UI = 31–37 $\mu\text{g}/\text{L}$). In the treated group, median UI increased threefold and thyroid volume did not change. In the controls, there was no change

TABLE 3. NEWBORN THYROTROPIN CONCENTRATIONS (DAYS 3 AND 4 AFTER BIRTH) FROM THE NEWBORN SCREENING PROGRAM FOR EASTERN SWITZERLAND IN 1992–1998 (BEFORE THE INCREASE IN SALT IODINE CONCENTRATION FROM 15 TO 20 MG/KG) COMPARED WITH 1999–2004 (AFTER THE INCREASE) (DATA FROM REF. 29)

	Study year 1992–1998 (n = 259,035)	Study year 1999–2004 (n = 218,665)
Newborn whole-blood TSH (mU/L) ^a	1.2 (0.8–1.9)	1.2 (0.8–1.8)
Prevalence of newborn TSH >5 mU/L (%)	2.9	1.7 ^b

^aMedian; interquartile range in parentheses (all such values).

^bSignificantly different from 1992–1998, $p < 0.0001$ (chi-square test).

in UI, but a 16% increase in thyroid volume. Treatment had no effect on maternal TSH. Pedersen *et al.* (31) randomized pregnant women ($n = 54$) to receive either 200 μg iodine/day as potassium iodide solution or no supplement from 17 weeks to term. Median UI increased from 55 $\mu\text{g}/\text{L}$ to 90–110 $\mu\text{g}/\text{L}$ in treated group. Maternal thyroid volume increased 16% in the treated group versus 30% in controls. Maternal serum thyroglobulin (Tg) and TSH, and cord Tg were significantly lower in the treated group. No significant differences were found between groups when maternal or cord T4, triiodothyronine (T3), and FT4 were compared. In a double-blind, placebo-controlled trial, Glinoe *et al.* (32) supplemented pregnant women ($n = 120$; median UI = 36 $\mu\text{g}/\text{L}$; biochemical criteria of excess thyroid stimulation) with 100 μg iodine/day or control from ~14 weeks to term. Treatment had no significant effect on maternal or cord T3, FT4, and T3/T4 ratio. The treated women had significantly higher UI, smaller thyroid volumes, and lower TSH and Tg concentrations, compared to controls. Newborns of the treated group also had significantly higher UI, smaller thyroid volumes, and lower Tg concentrations compared to controls.

Liesenkötter *et al.* (33) reported results from a controlled trial of 230 μg iodine/day from 11 weeks to term in pregnant women ($n = 108$; median UI 53 $\mu\text{g}/\text{g}$ creatinine (cr); goiter rate 43%). Median UI increased to 104 $\mu\text{g}/\text{g}$ cr in the treated group, and median thyroid volume was significantly lower in the newborns of the treated women compared to controls (0.7 mL vs. 1.5 mL, respectively). Treatment had no significant effect on maternal TSH, T3, T4, thyroid volume, or Tg, and had no effect on newborn TSH. In a placebo-controlled, double-blind trial, Nohr *et al.* (34) gave a multinutrient supplement containing 150 μg iodine/day or control to pregnant women positive for antithyroid peroxidase antibodies ($n = 66$) from 11 weeks to term. Median UI was significantly higher in the treated women at term, but there were no differences in maternal TSH, FT4, or Tg between groups. In a prospective, randomized, open-label trial, Antonangeli *et al.* (35) supplemented pregnant women ($n = 67$; median UI 74 $\mu\text{g}/\text{g}$ cr) with 50 μg or 200 μg iodine/day from 18–26 weeks to 29–33 weeks. Median UI was significantly higher in the 200 μg group than in the 50 μg group (230 $\mu\text{g}/\text{g}$ cr vs. 128 $\mu\text{g}/\text{g}$ cr). However, there were no differences in maternal FT4, free T3 (FT3), TSH, Tg, or thyroid volume between groups.

Summarizing the results of these trials (30–35), supplementation significantly increased maternal UI in all studies. Iodine doses varied between 50 and 230 $\mu\text{g}/\text{day}$, and the data indicate no clear dose–response relationship for UI, TSH, Tg, thyroid hormones, or thyroid volume. In three of the five trials that measured maternal thyroid volume, supplementation was associated with significantly reduced maternal thyroid size, and the data also suggest an increase in newborn thyroid volume and Tg can be prevented or minimized by supplementation. The data are equivocal for an effect on maternal TSH; values are generally lower (within the normal reference range) with iodine supplementation. It is important to point out that in these mild-to-moderately iodine-deficient pregnant women, supplementation had no effect on maternal and newborn total or free thyroid hormone concentrations (36). Moreover, there are no clinical data on the effect of iodine supplementation on birth outcomes, and no data on long-term outcomes, such as maternal goiter, thyroid autoimmunity, or child development.

Moderate Iodine Deficiency Adversely Affects Cognition in Children

Globally, 35% of schoolchildren, or 285 million children, have inadequate iodine intakes (37). Although the adverse effects of iodine deficiency *in utero* on neuromotor development of the offspring are well established (2–4), the post-natal effects of iodine deficiency on cognitive function are less clear. Observational studies of children living in iodine-deficient areas have generally found evidence of impaired intellectual function and fine motor skills compared to children in iodine-sufficient areas (38–40). From a meta-analysis of these and other studies, it has been estimated that populations with chronic iodine deficiency experience a reduction of 13.5 points in intelligence (41). Although this evidence is suggestive, observational studies are often confounded by other environmental factors that affect child development, such as health, socioeconomic status, and the accessibility and quality of education (42). Moreover, these studies could not distinguish between the persistent effects of *in utero* iodine deficiency and the effects of current iodine status. Several randomized trials have examined the impact of iodine supplementation on the cognitive performance of children, but their results are equivocal, and methodological problems limit their interpretation (43–49).

Thus, although school-age children are a main target group of iodine prophylaxis (14), the benefits of iodine repletion in this age group are unclear. For a child born and raised under conditions of iodine deficiency, is iodine treatment beneficial? The aim of a recent study was to determine whether providing iodized oil to iodine-deficient children would affect their cognitive and motor performance (50). In a double-blind intervention trial, 10- to 12-year-old children ($n = 310$) in rural primary schools in southeastern Albania were randomized to receive either 400 mg of iodine as oral iodized oil or placebo. UI, thyroid functions, and thyroid gland volume were measured. The children were given a battery of seven cognitive and motor tests that included measures of information processing, working memory, visual problem solving, visual search, and fine motor skills. Thyroid ultrasound and the biochemical and psychological tests were repeated after 24 weeks. At baseline, the children had a median UI

of 43 $\mu\text{g/L}$, and 87% were goitrous. Although mean total T4 (TT4) was within the normal range, nearly one-third of the children had low levels of TT4. Treatment with iodine markedly improved iodine and thyroid status: at 24 weeks, median UI in the treated group was 172 $\mu\text{g/L}$, mean TT4 increased $\approx 40\%$, and the prevalence of hypothyroxinemia was $<1\%$. Compared to placebo, iodine treatment significantly improved performance on four out of seven tests: rapid target marking, symbol search, rapid naming, and Raven's matrices ($p < 0.0001$) (Table 4). These findings suggest that information processing, fine motor skills, and visual problem solving are improved by iodine repletion in moderately iodine-deficient school-age children (50).

Moderate Iodine Deficiency Impairs Growth in Children

Severe iodine deficiency *in utero* causes cretinism and dwarfism (14). Iodized oil given during pregnancy in areas of moderate iodine deficiency increases birth weight (51,52). Less clear is the relationship between iodine deficiency and postnatal growth. Data from cross-sectional studies on iodine intake and child growth are mixed (53–58), with most studies finding modest positive correlations. In five Asian countries, household access to iodized salt was correlated with increased weight-for-age and mid-upper-arm circumference in infancy (59). However, controlled intervention studies of iodized oil alone (60,61) and iodine given with

TABLE 4. AGE, CONCENTRATIONS OF URINARY IODINE, WHOLE-BLOOD THYROID-STIMULATING HORMONE (TSH), SERUM TOTAL THYROXINE (TT4), INSULIN-LIKE GROWTH FACTOR (IGF)-1, INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN (IGFBP)-3, HEIGHT- AND WEIGHT-FOR-AGE z-SCORES, AND COGNITIVE AND MOTOR TESTS IN 10- TO 12-YEAR-OLD ALBANIAN CHILDREN AT BASELINE AND 6 MONTHS AFTER RECEIVING EITHER 400 MG OF IODINE AS ORAL IODIZED OIL OR PLACEBO (DATA FROM REFS. 50 AND 80)

Variable	Time (months)	Iodine	Control
N		159	151
Age (years) ^a		11.3 \pm 0.8	11.5 \pm 0.8
Urinary iodine ($\mu\text{g/L}$) ^{b,c}	0	42 (0–186)	44 (0–215)
	6	172 (18–724) ^{e,h}	49 (3–221)
TSH (mU/L) ^b	0	1.6 (0.6–5.0)	1.8 (0.8–5.2)
	6	1.4 (0.4–5.2)	1.6 (0.4–15.4)
TT4 (nmol/L) ^{a,c}	0	76 \pm 17	75 \pm 17
	6	106 \pm 18 ^{f,i}	81 \pm 19
Growth			
IGF-1 (ng/mL) ^{b,c}	0	147 (25–587)	139 (25–540)
	6	229 (71–627) ^{f,g}	178 (73–497) ^d
IGFBP-3 ($\mu\text{g/mL}$) ^{b,c}	0	3.1 (1.8–5.5)	3.3 (1.9–5.4)
	6	4.5 (1.0–7.2) ^{d,g}	3.7 (1.9–5.7)
Height-for-age z-score ^{b,c}	0	–1.17 (–4.33 to –1.22)	–1.08 (–3.69 to –2.23)
	6	–0.82 (–3.94 to –1.48) ^{d,g}	–1.03 (–3.61 to –1.83)
Weight-for-age z-score ^{b,c}	0	–0.77 (–2.77 to –0.91)	–0.83 (–2.68 to –1.92)
	6	–0.53 (–2.74 to –1.36) ^{d,g}	–0.70 (–2.58 to –2.22)
Cognitive and motor tests			
Ravens matrices ^j	0	17.0 \pm 5.4	19.9 \pm 6.3
	6	24.0 \pm 6.3	20.5 \pm 5.6
Adjusted treatment effect (95% CI)			4.7 (3.8, 5.8)
Rapid target marking ^j	0	37.0 \pm 12.6	34.2 \pm 10.8
	6	29.5 \pm 6.6	31.0 \pm 7.2
Adjusted treatment effect (95% CI)			2.8 (1.6, 4.0)
Symbol search ^j	0	17.3 \pm 5.2	19.7 \pm 4.8
	6	21.8 \pm 4.5	20.5 \pm 5.2
Adjusted treatment effect (95% CI)			2.8 (1.9, 3.6)
Rapid naming ^j	0	52.9 \pm 15.1	49.9 \pm 16.6
	6	42.5 \pm 10.6	45.2 \pm 13.5
Adjusted treatment effect (95% CI)			4.5 (2.3, 6.6)

^aMean \pm SD.

^bMedian (range).

^cSignificant interaction (time \times treatment) (ANOVA); $p < 0.0001$.

^{d–f}Different from baseline (paired Wilcoxon test); ^d $p < 0.05$; ^e $p < 0.001$; ^f $p < 0.01$.

^{g–i}Different from control (unpaired Wilcoxon test); ^g $p < 0.05$; ^h $p < 0.001$; ⁱ $p < 0.01$.

^jSignificant differences by mixed model ANOVA ($p < 0.0001$), adjusted for baseline, school, and gender. Baseline value was used as a fixed effect.

other micronutrients (62–64) have generally not found effects on child growth.

Iodine status may influence growth through its effects on the thyroid axis. Administration of T4 to hypothyroid children increases their growth (65). Thyroid hormone promotes growth hormone (GH) secretion and modulates the effects of GH at its receptor (66–68). Insulin-like growth factor (IGF)-1 and insulin-like growth factor-binding protein (IGFBP)-3 are also dependent on thyroid status (69–73). In humans, hypothyroidism decreases circulating IGF-1 and IGFBP-3 levels, and thyroid hormone replacement increases them (74,75). In iodine-deficient children, impaired thyroid function and goiter are inversely correlated with IGF-1 and IGFBP-3 concentrations (76–78). However, in an uncontrolled trial, oral iodized oil decreased IGF-I and IGFBP-3 concentrations in Turkish children (79). The aim of a recent study (80) was to determine whether iodine repletion improves growth in school-age children, and to investigate the role of IGF-1 and IGFBP-3 in this effect. Three prospective, double-blind intervention studies were done: (i) in a 10-month study, severely iodine-deficient, 7- to 10-year-old Moroccan children ($n=71$) were provided iodized salt and compared to children not using iodized salt; (ii) in a 6-month study, moderately iodine-deficient, 10- to 12-year-old Albanian children ($n=310$) were given 400 mg iodine as oral iodized oil or placebo; (iii) in a 6-month study, mildly iodine-deficient 5- to 14-year-old South African children ($n=188$) were given two doses of 200 mg iodine as oral iodized oil or placebo. At baseline and follow-up, height, weight, UI, TT4, TSH, and IGF-I were measured; in Albania and South Africa, IGFBP-3 was also measured. In all three studies, iodine treatment increased median UI to $>100 \mu\text{g/L}$, while median UI in the controls remained unchanged. In South Africa, iodine repletion modestly increased IGF-1, but did not have a significant effect on IGFBP-3, TT4, or growth. In Albania and Morocco, iodine repletion significantly increased TT4, IGF-1, IGFBP-3, weight-for-age z-scores, and height-for-age z-scores (Table 4). This is the first controlled study to clearly demonstrate that iodine repletion in school-age children increases IGF-1 and IGFBP-3 concentrations and improves somatic growth (80).

References

1. World Health Organization, United Nations Children's Fund, International Council for the Control of Iodine Deficiency Disorders 2001 Assessment of iodine deficiency disorders and monitoring their elimination. WHO, Geneva: WHO/NHD/01.1.
2. Pharoah PO, Connolly KJ 1987 A controlled trial of iodinated oil for the prevention of endemic cretinism: a long-term follow-up. *Int J Epidemiol* **16**:68–73.
3. Cao XY, Jiang XM, Dou ZH, Rakeman MA, Zhang ML, O'Donnell K, Ma T, Amette K, DeLong N, DeLong GR 1994 Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. *N Engl J Med* **331**:1739–1744.
4. Connolly KJ, Pharoah PO, Hetzel BS 1979 Fetal iodine deficiency and motor performance during childhood. *Lancet* **2**: 1149–1151.
5. Sack J 2003 Thyroid function in pregnancy—maternal-fetal relationship in health and disease. *Pediatr Endocrinol Rev* **1**(Suppl 2):170–176.
6. Vulmsa T, Gons MH, de Vijlder JJ 1989 Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. *N Engl J Med* **321**:13–16.
7. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulmsa T, Wiersinga WM, Drexhage HA, Vader HL 1999 Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol (Oxf)* **50**:149–155.
8. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* **341**:549–555.
9. Glinioer D 2006 Iodine nutrition requirements during pregnancy. *Thyroid* **16**:947–948.
10. Aboul-Khair SA, Crooks J, Turnbull AC, Hytten FE 1964 The physiological changes in thyroid function during pregnancy. *Clin Sci* **27**:195–207.
11. Liberman CS, Pino SC, Fang SL, Braverman LE, Emerson CH 1998 Circulating iodide concentrations during and after pregnancy. *J Clin Endocrinol Metab* **83**:3545–3549.
12. Institute of Medicine, Academy of Sciences, USA 2001 Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. National Academy Press, Washington DC, pp 1–773.
13. Dworkin HJ, Jacquez JA, Beierwaltes WH 1966 Relationship of iodine ingestion to iodine excretion in pregnancy. *J Clin Endocrinol Metab* **26**:1329–1342.
14. WHO, UNICEF, ICCIDD 2001 Assessment of the iodine deficiency disorders and monitoring their elimination. WHO publ. WHO/NHD/01.1, Geneva, pp 1–107.
15. Proceedings of the WHO Technical Consultation on control of iodine deficiency in pregnant women and young children. Geneva, February 2005.
16. Mattsson S, Lindstrom S 1995 Diuresis and voiding pattern in healthy schoolchildren. *Br J Urol* **76**:783–789.
17. Larsson G, Victor A 1988 Micturition patterns in a healthy female population, studied with a frequency/volume chart. *Scand J Urol Nephrol* **114**:53–57.
18. Dafnis E, Sabatini S 1992 The effect of pregnancy on renal function: physiology and pathophysiology. *Am J Med Sci* **303**: 184–205.
19. Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter EW, Maberly GF, Braverman LE, Pino S, Miller DT, Garbe PL, DeLozier DM, Jackson RJ 1998 Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971–1974 and 1988–1994). *J Clin Endocrinol Metab* **83**:3401–3408.
20. Andersen S, Pedersen KM, Pedersen IB, Laurberg P 2001 Variations in urinary iodine excretion and thyroid function. A 1-year study in healthy men. *Eur J Endocrinol* **144**:461–465.
21. Soldin OP, Tractenberg RE, Pezzullo JC 2005 Do thyroxine and thyroid-stimulating hormone levels reflect urinary iodine concentrations? *Ther Drug Monit* **27**:178–185.
22. Delange F, Heidemann P, Bourdoux P, Larsson A, Vigneri R, Klett M, Beckers C, Stubbe P 1986 Regional variations of iodine nutrition and thyroid function during the neonatal period in Europe. *Biol Neonate* **49**:322–330.
23. Nordenberg D, Sullivan K, Maberly G, Wiley V, Wilcken B, Bamforth F, Jenkins M, Hannon H, Adam B 1993 Congenital hypothyroid screening programs and the sensitive

- thyrotropin assay: strategies for the surveillance of iodine deficiency disorders. In: Delange F, Dunn J, Glinoe D (eds) *Iodine Deficiency in Europe: A Continuing Concern*. Plenum Publishing, New York, pp 211–217.
24. Carta Sorcini M, Diodato A, Fazzini C, Sabini G, Carta S, Grandolfo ME, Guidi M, Vasta M, De Maestri JL, Donati L 1988 Influence of environmental iodine deficiency on neonatal thyroid screening results. *J Endocrinol Invest* **11**:309–312.
 25. Sullivan KM, May W, Nordenberg D, Houston R, Maberly GF 1997 Use of thyroid stimulating hormone testing in newborns to identify iodine deficiency. *J Nutr* **127**:55–58.
 26. Copeland DL, Sullivan KM, Houston R, May W, Mendoza I, Salamatullah Q, Solomons N, Nordenberg D, Maberly GF 2002 Comparison of neonatal thyroid-stimulating hormone levels and indicators of iodine deficiency in school children. *Public Health Nutr* **5**:81–87.
 27. McElduff A, McElduff P, Gunton JE, Hams G, Wiley V, Wilcken BM 2002 Neonatal thyroid-stimulating hormone concentrations in northern Sydney: further indications of mild iodine deficiency? *Med J Aust* **176**:317–320.
 28. WHO/ICCIDD/UNICEF 1994 Indicators for assessing iodine deficiency disorders and their control through salt iodization. Geneva, WHO/NUT/94.6.
 29. Zimmermann MB, Aeberli I, Torresani T, Bürgi H 2005 Increasing the iodine concentration in the Swiss iodized salt program markedly improves iodine status in pregnant women and children: a 5-yr prospective national study. *Am J Clin Nutr* **88**:388–392.
 30. Romano R, Jannini EA, Pepe M, Grimaldi A, Olivieri M, Spennati P, Cappa F, D'Armiento M 1991 The effects of iodoprophylaxis on thyroid size during pregnancy. *Am J Obstet Gynecol* **164**:482–485.
 31. Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen OS, Larsen KR, Eriksen GM, Johannesen PL 1993 Amelioration of some pregnancy-associated variations in thyroid function by iodine supplementation. *J Clin Endocrinol Metab* **77**:1078–1083.
 32. Glinoe D, De Nayer P, Delange F, Lemone M, Toppet V, Spehl M, Grun JP, Kinthaert J, Lejeune B 1995 A randomized trial for the treatment of mild iodine deficiency during pregnancy: maternal and neonatal effects. *J Clin Endocrinol Metab* **80**:258–269.
 33. Liesenkötter KP, Göpel W, Bogner U, Stach B, Grüters A 1996 Earliest prevention of endemic goiter by iodine supplementation during pregnancy. *Eur J Endocrinol* **134**:443–448.
 34. Nohr SB, Jorgensen A, Pedersen KM, Laurberg P 2000 Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? *J Clin Endocrinol Metab* **85**:3191–3198.
 35. Antonangeli L, Maccherini D, Cavaliere R, Giulio CD, Reinhardt B, Pinchera A, Aghini-Lombardi F 2002 Comparison of two different doses of iodide in the prevention of gestational goiter in marginal iodine deficiency: a longitudinal study. *Eur J Endocrinol* **147**:29–34.
 36. Zimmermann MB, Delange F 2004 Iodine supplementation in pregnant women in Europe: a review and recommendations. *Eur J Clin Nutr* **58**:979–84.
 37. de Benoist B, Andersson M, Takkouche B, Egli I 2003 Prevalence of iodine deficiency worldwide. *Lancet* **362**:1859–1860.
 38. Boyages SC, Collins JK, Maberly GF, Jupp JJ, Morris J, Eastman CJ 1989 Iodine deficiency impairs intellectual and neuromotor development in apparently-normal persons. A study of rural inhabitants of north-central China. *Med J Aust* **150**:676–682.
 39. Tiwari BD, Godbole MM, Chattopadhyay N, Mandal A, Mithal A 1996 Learning disabilities and poor motivation to achieve due to prolonged iodine deficiency. *Am J Clin Nutr* **63**:782–786.
 40. Vermiglio F, Sidoti M, Finocchiaro MD, Battiato S, Lo Presti VP, Benvenuta S, Trimarchi F 1990 Defective neuromotor and cognitive ability in iodine-deficient schoolchildren of an endemic goiter region in Sicily. *J Clin Endocrinol Metab* **70**:379–384.
 41. Bleichrodt N, Born MP 1994 A metaanalysis of research on iodine and its relationship to cognitive development. In: Stanbury JB (ed) *The Damaged Brain of Iodine Deficiency*. Cognizant Communication, New York, pp 195–200.
 42. Sameroff AJ, Seifer R, Baldwin A, Baldwin C 1993 Stability and intelligence from preschool to adolescence: the influence of social and family risk factors. *Child Dev* **64**:80–97.
 43. Bautista A, Barker PA, Dunn JT, Sanchez M, Kaiser DL 1982 The effects of oral iodized oil on intelligence, thyroid status, and somatic growth in school-age children from an area of endemic goiter. *Am J Clin Nutr* **35**:127–134.
 44. Shrestha RM 1994 Effect of iodine and iron supplementation on physical, psychomotor and mental development in primary school children in Malawi. Doctoral thesis, Wageningen Agricultural University, Wageningen, The Netherlands.
 45. Huda SN, Grantham-McGregor SM, Tomkins A 2001 Cognitive and motor functions of iodine deficient but euthyroid children in Bangladesh do not benefit from iodized poppy seed oil (lipiodol). *J Nutr* **31**:72–77.
 46. Isa ZM, Alias IZ, Kadir KA, Ali O 2000 Effect of iodized oil supplementation on thyroid hormone levels and mental performance among Orang Asli schoolchildren and pregnant mothers in an endemic goitre area in Peninsular Malaysia. *Asia Pac J Clin Nutr* **9**:274–281.
 47. Downing DC, Geelhoed GW 1994 Goitre and cretinism in the Uele Zaire endemia: studies of an iodine-deficient population with change following intervention. II. Functional and behavioral aspects. In: Stanbury J.B. (ed) *The Damaged Brain of Iodine Deficiency*. Cognizant Communication, New York, pp 233–239.
 48. van den Briel T, West CE, Bleichrodt N, van de Vijver FJ, Atebo EA, Hautvast JG 2000 Improved iodine status is associated with improved mental performance of schoolchildren in Benin. *Am J Clin Nutr* **72**:1179–1185.
 49. Qian M, Wang D, Watkins WE, Gebiski V, Yan YQ, Li M, Chen ZP 2005 The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. *Asia Pac J Clin Nutr* **14**:32–42.
 50. Zimmermann MB, Connolly K, Bozo M, Bridson J, Rohner F, Grimci L 2006 Iodine supplementation improves cognition in iodine-deficient schoolchildren in Albania: a randomized, controlled, double-blind study. *Am J Clin Nutr* **83**:108–114.
 51. Chaouki ML, Benmoulid M 1994 Prevention of iodine deficiency disorders by oral administration of lipiodol during pregnancy. *Eur J Endocrinol* **130**:547–551.
 52. Koutras DA, Christakis G, Trichopoulos D, Dakou-Voutetaki A, Kyriakopoulos V, Fontaneres P, Livadas DP, Gatsios D, Malamou B 1973 Endemic goiter in Greece: nutritional status, growth, and skeletal development of goitrous and non-goitrous populations. *Am J Clin Nutr* **26**:1360–1368.
 53. Bautista A, Barker PA, Dunn JT, Sanchez M 1977 Lack of correlation between thyroid size and body growth in an area of endemic goiter. *Am J Clin Nutr* **30**:275–279.

54. Ali O, Tan TT, Sakinah O, Khalid BA, Wu LL, Wan Nazaimoon WM, Ng ML 1994 Thyroid function and pubertal development in malnutrition. *Ann Acad Med Singapore* **23**: 852–855.
55. Azizi F, Kalani H, Kimiagar M, Ghazi A, Sarshar A, Nafarabadi M, Rahbar N, Noohi S, Mohajer M, Yassai M 1995 Physical, neuromotor and intellectual impairment in non-cretinous school children with iodine deficiency. *Int J Vitam Nutr Res* **65**:199–205.
56. Neumann CG, Harrison GG 1994 Onset and evolution of stunting in infants and children. Examples from the Human Nutrition Collaborative Research Support Program. Kenya and Egypt studies. *Eur J Clin Nutr* **48(Suppl 1)**:S90–S102.
57. Lal RB, Srivastava VK, Chandra R 1996 A study of the spectrum of iodine deficiency disorders in rural area of Uttar Pradesh. *Indian J Public Health* **40**:10–12.
58. Thurlow RA, Winichagoon P, Pongcharoen T, Gowachirapant S, Boonpradern A, Manger MS, Bailey KB, Wasantwisut E, Gibson RS 2006 Risk of zinc, iodine and other micronutrient deficiencies among school children in North East Thailand. *Eur J Clin Nutr* **60**:623–632.
59. Mason JB, Deitchler M, Gilman A, Gillenwater K, Shuaib M, Hotchkiss D, Mason K, Mock N, Sethuraman K 2002 Iodine fortification is related to increased weight-for-age and birthweight in children in Asia. *Food Nutr Bull* **23**:292–308.
60. Bautista S, Barker PA, Dunn JT, Sanchez M, Kaiser DL 1982 The effects of oral iodized oil on intelligence, thyroid status, and somatic growth in school-age children from an area of endemic goiter. *Am J Clin Nutr* **35**:127–134.
61. Huda SN, Grantham-McGregor SM, Tomkins A 2001 Cognitive and motor functions of iodine-deficient but euthyroid children in Bangladesh do not benefit from iodized poppy seed oil (Lipiiodol). *J Nutr* **131**:72–77.
62. van Stuijvenberg ME, Kvalsvig JD, Faber M, Kruger M, Kenoyer DG, Benade AJ 1999 Effect of iron-, iodine-, and beta-carotene-fortified biscuits on the micronutrient status of primary school children: a randomized controlled trial. *Am J Clin Nutr* **69**:497–503.
63. Rivera JA, Gonzalez-Cossio T, Flores M, Romero M, Rivera M, Tellez-Rojo MM, Rosado JL, Brown KH 2001 Multiple micronutrient supplementation increases the growth of Mexican infants. *Am J Clin Nutr* **74**:657–663.
64. Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT, Neve J, Perlmutter N, Vanderpas J 2003 Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. *Am J Clin Nutr* **78**:137–144.
65. Hernandez-Cassis C, Cure-Cure C, Lopez-Jaramillo P 1995 Effect of thyroid replacement therapy on the stature of Colombian children with minimal thyroid dysfunction. *Eur J Clin Invest* **25**:454–456.
66. Crews MD, Spindler SR 1989 Thyroid hormone regulation of the transvected rat growth hormone promoter. *J Biol Chem* **261**:5018–5022.
67. Samuels MH, Wierman ME, Wang C, Ridgway EC 1989 The effect of altered thyroid status on pituitary hormone messenger ribonucleic acid concentration in the rat. *Endocrinology* **124**:2277–2282.
68. Hochberg Z, Bick T, Harel Z 1990 Alterations of human growth hormone binding by rat liver membranes during hypo- and hyperthyroidism. *Endocrinology* **126**:325–329.
69. Burstein PJ, Draznin B, Johnson CJ, Schalch DS 1979 The effect of hypothyroidism on growth, serum growth hormone, the growth hormone-dependent somatomedin, insulin-like growth factor, and its carrier protein in rats. *Endocrinology* **104**:1107–1111.
70. Geary ES, Lim M, Ceda GI, Ro S, Rosenfeld RG, Hoffman AR 1989 Triiodothyronine regulates insulin-like growth factor-I binding to cultured rat pituitary cells. *J Neuroendocrinol* **1**: 179–184.
71. Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R 1993 Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. *J Clin Endocrinol Metab* **76**:950–955.
72. Angerva M, Toivonen J, Leinonen P, Valimaki M, Seppala M 1993 Thyroxine withdrawal is accompanied by decreased circulating levels of insulin-like growth factor binding protein-1 in thyroidectomized patients. *J Clin Endocrinol Metab* **76**:1199–1201.
73. Nanto-Salonen K, Muller HL, Hoffman AR, Vu TH, Rosenfeld RG 1993 Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated. *Endocrinology* **132**:781–788.
74. Miell JP, Zini M, Quin JD, Jones J, Portioli I, Valcavi R 1994 Reversible effects of cessation and recommencement of thyroxine treatment on insulin-like growth factors (IGFs) and IGF-binding proteins in patients with total thyroidectomy. *J Clin Endocrinol Metab* **79**:1507–1512.
75. Iglesias P, Bayon C, Mendez J, Gancedo PG, Grande C, Diez JJ 2001 Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction. *Thyroid* **11**:1043–1048.
76. Wan Nazaimoon WM, Osman A, Wu LL, Khalid BA 1996 Effects of iodine deficiency on insulin-like growth factor-I, insulin-like growth factor-binding protein-3 levels and height attainment in malnourished children. *Clin Endocrinol* **45**: 79–83.
77. Aydin K, Bideci A, Kendirci M, Cinaz P, Kurtoglu S 2002 Insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels of children living in an iodine- and selenium-deficient endemic goiter area. *Biol Trace Elem Res* **90**:25–30.
78. Alikasifoglu A, Özön A, Yordam N 2002 Serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels in severe iodine deficiency. *Turk J Pediatr* **44**:215–218.
79. Ozon A, Alikasifoglu A, Yordam N 2004 Influence of iodine supplementation on serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) levels in severe iodine deficiency. *Turk J Pediatr* **46**:303–308.
80. Zimmermann MB, Jooste PL, Mabapa NS, Mbhenyane X, Schoeman S, Biebinger R, Chaouki N, Bozo M, Grimci L, Bridson J 2007 Treatment of iodine deficiency in school-age children increases IGF-1 and IGFBP-3 concentrations and improves somatic growth. *J Clin Endocrinol Metab* **92**(2):437–42.

Address reprint requests to:

Michael B. Zimmermann
Laboratory for Human Nutrition
Swiss Federal Institute of Technology
Schmelzbergstrasse 7, LFV E19
CH-8092 Zürich
Switzerland

E-mail: michael.zimmermann@ilw.agrl.ethz.ch

